-
Recent Posts
- Dementia Moonshot Report: Research Priorities and Costs (Alzheimer’s Research UK)
- Dementia-Related Hospital Admissions (BBC News / Alzheimer’s Society)
- NHS Demands Action to Reduce Betting-Related Ill Health (BBC News / NHS England / Respublica)
- Research and Innovation Across the NHS and Academia (BBC News / Academy of Medical Sciences)
- eHealth / Internet-Based Interventions to Support Carers of People With Dementia (Internet Interventions)
Archives
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Misfolded Proteins
The Most Significant Breakthrough in the Treatment of Neurodegenerative Diseases in Fifty Years? (BBC News / UCL)
Summary An experimental drug for the treatment of Huntington’s Disease shows early signs of being able to lower the level of misfolded proteins (safely) in the brains of patients, thereby having the potential to slow or halt the progression of … Continue reading
Posted in BBC News, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Parkinson's Disease, Quick Insights, UK, Universal Interest
Tagged Alzheimer's Disease, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Antisense Oligonucleotides (ASO), Biomedical Research Centres (NIHR), Canada, Clinical Trial NCT02519036, Gene Silencing to Suppress Transcription and Translation of Huntingtin, Gene-Silencing, Genetic Research, Genetics, Germany, Huntingtin Protein, Huntingtin Protein (HTT), Huntington Disease, Huntington's Disease (HD): an Autosomal-Dominant Inherited Neurodegenerative Disorder, Huntington's Disease Centre: UCL Institute of Neurology, Huntington’s Disease, Ionis Pharmaceuticals, IONIS-HTTRx: Huntingtin-Lowering Drug, α-Synuclein, α-Synuclein Aggregation, Leonard Wolfson Experimental Neurology Centre (LWENC), Leonard Wolfson Experimental Neurology Centre: University College London, Misfolded Proteins, Mutant HTT (mHTT) Protein, Mutant Huntingtin (mHTT), National Institute for Health Research (NIHR), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuronal Loss, Neuroprotection, Prof. Giovanna Mallucci, Professor Sarah Tabrizi: IONIS-HTTRx Global Chief Investigator, Professor Sarah Tabrizi: UCL Institute of Neurology, Protein Misfolding, Roche, Synucleinopathy, Tau, Tau Protein, Tauopathy, University College London (UCL), University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, University College London Hospitals NHS Foundation Trust / University College London (NIHR) Biomedical Research Centre
Leave a comment
Structure of Tau Filaments in Alzheimer’s Disease Discovered (MRC / BBC News / Nature / NHS Choices)
Summary Research at the MRC Laboratory of Molecular Biology has taken advantage of a “resolution revolution” in microscopy to uncover the atomic structure of Tau filaments (one of the two types of the abnormal tangles associated with Alzheimer’s Disease). “Tau forms … Continue reading
Posted in BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, National, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, UK, Universal Interest
Tagged Abnormal Proteins, Abnormal Proteins (Alpha-Synuclein), Abnormal Proteins (Prions), Abnormal Proteins (Tau), Alzheimer’s Disease, Amyloid and Tau Imaging, Atomic Structure of Tau Filaments, BBC Health News, Behind the Headlines, Cryo-Electron Microscopy (Cryo-EM), Cryo-EM Structures of PHFs and SFs, Cryo-EM Structures of Tau Filaments, Department of Pathology and Laboratory Medicine: Indiana University School of Medicine, Drug Trials Failure Rate, European Union, Indiana University, Indiana University School of Medicine, Laboratory of Molecular Biology (LMB) Neuroscience Division, Medical Research Council (MRC), Misfolded Proteins, MRC Laboratory of Molecular Biology, MRC Laboratory of Molecular Biology (LMB), MRC Laboratory of Molecular Biology: Cambridge, MRC: Medical Research Council, Nature, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Research, Neurofibrillary Tangles, Neurofibrillary Tangles (NFTs), Neuropathologic Disorders, Neuropathology, Novel Targets in Neurodegeneration, Paired Helical Filaments (PHFs) and Straight Filaments (SFs), Protein Misfolding, Protofilament Interface in PHFs and SFs, Tau, Tau Aggregation, Tau Filaments, Tau Pathogenesis, Tau Pathology, Tau Protein, Tauopathy, Ultrastructural Polymorphs, United States, US National Institutes of Health, USA
Leave a comment
Another Recent Alzheimer’s Disease Drug Trial Disappointment (Lancet)
Summary Researchers aimed to discover whether LMTM [Leuco-methylthioninium bis(hydromethanesulfonate] might be safe and effective for slowing disease progression in patients with mild to moderate Alzheimer’s Disease. LMTM had previously been found to work as a selective inhibitor of tau protein … Continue reading
Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Pharmacological Treatments, Quick Insights
Tagged Aberdeen Biomedical Imaging Centre: University of Aberdeen, Abnormal Proteins (Tau), Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog), Alzheimer's Disease Co-operative Study-Activities of Daily Living Inventory (ADCS-ADL) Scale, Alzheimer's Disease Research Unit, BioClinica (Lyon France), Canada, Clinicaltrials No. NCT01689246, CSD Biostatistics (USA), Department of Chemistry: University of Aberdeen, Department of Neurology: University of Southern California, Department of Neurosciences: University of California, Department of Psychiatry and Behavioral Sciences: University of Southern California, Douglas Mental Health University Institute (Montreal), Drug Trials, Drug Trials Failure Rate, European Union Clinical Trials Registry No. 2012-002866-11, France, Institute for Complex Systems and Mathematical Biology: University of Aberdeen, Keck School of Medicine: University of Southern California, Lancet, Leonard Davis School of Gerontology: University of Southern California, Leuco-Methylthioninium (LMTM), Leuco-Methylthioninium Bis(Hydromethanesulfonate): LMTM, McGill Centre for Studies in Aging, Medical Sciences and Nutrition: University of Aberdeen, Methaemoglobinaemia, Methylthioninium Chloride, Mild Alzheimer’s Disease, Misfolded Proteins, Moebius-Consult (Baar Switzerland), Nuffield Department of Clinical Neurosciences: University of Oxford, RadMD (USA), Reasons for Termination of Trials, Salamandra LLC (USA), School of Medicine: University of Aberdeen, School of Medicine: University of California, Switzerland, Tau, Tau Aggregation, Tau Aggregation Inhibitors, Tau Pathology, Tau Protein, Tau Tangles, Tau-Targeting Drugs, TauRx Therapeutics (Aberdeen), United States, University Hospitals and University of Geneva, University of Aberdeen, University of California, University of Oxford, University of Southern California, USA
Alzheimer’s Disease: Solanezumab Drug Trial Flops (BBC News / Alzheimer’s and Dementia)
Summary The phase 3 EXPEDITION3 trial has been abandoned, as Solanezumab failed to slow cognitive decline in tests on around 2,000 patients with Alzheimer’s Disease. Several other amyloid-clearance drugs are going through trials apparently. Full Text Link Reference Walsh, F. … Continue reading
Posted in BBC News, For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights, Universal Interest
Tagged Alzheimer’s and Dementia (Journal), Alzheimer’s Disease Clinical Trials, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Avid Radiopharmaceuticals (Philadelphia), BBC Health News, Big Pharma, Clearance of Amyloid Beta Protein, Drug Trials, Drug Trials Failure Rate, Eli Lilly, Eli Lilly and Company (Indianapolis), EXPEDITION Studies, Intervention Trials, β-amyloid, LZAM, LZAN, Mild Alzheimer’s Disease, Misfolded Proteins, Neurofibrillary Tangles, Neuronal Loss, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Reasons for Termination of Trials, Solanezumab (Eli Lilly), Solanezumab EXPEDITION Trials, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody, United States, USA
Leave a comment
